



TREATMENT OF OBSTETRIC/GYNECOLOGIC INFECTIONS

Clinical Setting	Empiric Therapy	Duration	Comments
<p>Pelvic Inflammatory Disease (Endometritis, Salpingitis, Tubo-ovarian abscess, pelvic peritonitis)</p> <ul style="list-style-type: none"> • <i>Neisseria gonorrhoeae</i> • <i>Chlamydia trachomatis</i> • Anaerobes • Enteric gram-negative rods • <i>Streptococcus agalactiae</i> • <i>Mycoplasma hominis</i> • <i>Ureaplasma urealyticum</i> 	<p><u>Empiric Regimen</u> Cefoxitin* 2 g IV q6h + Doxycycline 200 mg PO X 1, then 100 mg PO q12h</p> <p><u>Anaphylactic PCN/Cephalosporin Allergy</u> Clindamycin 900 mg IV q8h + Gentamicin* 5 mg/kg IV q24h + Azithromycin 2 g PO once</p> <p><u>Step Down Oral Therapy</u> <i>With tubo-ovarian abscess:</i> Doxycycline 100 mg PO q12h + Clindamycin 450 mg PO q6h OR Metronidazole 500 mg PO q8h</p> <p><i>Without tubo-ovarian abscess:</i> Doxycycline 100 mg PO q12h</p>	<p>General: 14 days at minimum</p> <p>Parenteral therapy can be switched to oral therapy 24-48 hours after clinical improvement.</p>	<ul style="list-style-type: none"> • In women with tubo-ovarian abscesses, at least 24 hours of inpatient observation is recommended. • Extended interval gentamicin dosing (5 mg/kg IV q24h) is preferred. Therapeutic drug monitoring may be necessary and dosing adjustments should be made with PharmD. • Duration of therapy should be a minimum of 14 days without drainage of tubo-ovarian abscess. Final duration should be dependent on resolution of the abscess on follow-up imaging studies. Some patients may require 4-6 weeks of antimicrobial therapy. • For <i>outpatient</i> management of mild-to-moderate PID: Ceftriaxone 250 mg IM x1 dose + Doxycycline 200 mg PO x1, then 100 mg PO q12h + Metronidazole 500 mg PO q8h. Women who do not respond to IM/oral therapy within 72 hours should be reevaluated to confirm the diagnosis and should be given intravenous therapy
<p>Post-operative intra-abdominal abscess or peritonitis after gynecologic surgery</p> <ul style="list-style-type: none"> • Gram-negative bacilli (<i>E. coli</i>, <i>okKlebsiella</i>, <i>Proteus</i>, <i>Pseudomonas</i>, <i>Enterobacter</i>) • Enteric gram-positive organisms (<i>Streptococcus</i>, <i>Enterococcus</i>) 	<p><u>Empiric Regimen:</u> Piperacillin-tazobactam* 4.5 g IV q6h</p> <p><u>PCN Allergy without Anaphylaxis, Angioedema, or Urticaria</u> Cefepime* 2 g IV q8h + Metronidazole 500 mg PO/IV q8h</p> <p>Consider the addition of vancomycin** for Enterococcus coverage in critically ill patients with non-life-threatening PCN allergy</p> <p><u>Anaphylactic Reaction to PCN</u> Vancomycin** IV (see nomogram, AUC goal 400-600) + Aztreonam* 2 g IV q8h + Metronidazole 500 mg PO/IV q8h</p>	<p>General: 5-7 days</p> <p>Duration of therapy may be extended with inadequate source control or persistent clinical symptoms or signs of infection.</p>	<ul style="list-style-type: none"> • Ampicillin/sulbactam is not recommended for use because of high rates of resistance among community-acquired <i>E. coli</i>. • Adjust antimicrobial coverage based on organism identification and antimicrobial susceptibilities. • <i>Enterococcus</i> coverage: Empiric antimicrobial coverage for vancomycin resistant enterococcus (VRE) is not recommended except in critically ill liver transplant recipients, patients with a previous history of VRE intra-abdominal infection, or patients with septic shock who are colonized with VRE. Linezolid 600 mg PO/IV q12h can be considered empirically but should be discontinued if VRE is not identified on blood culture. • MRSA coverage: Empiric MRSA antimicrobial coverage should only be provided to patients with post-operative peritonitis who are known to be colonized with MRSA and discontinued if MRSA is not recovered in culture

Clinical Setting	Empiric Therapy	Duration	Comments
<p>Chorioamnionitis</p> <ul style="list-style-type: none"> Anaerobes <i>Gardnerella vaginalis</i> Group B streptococcus <i>Clostridium spp.</i> Enterobacteriaceae <i>Chlamydia trachomatis</i> <i>Mycoplasma</i> <i>Ureaplasma</i> <i>S. aureus</i> 	<p><u>Empiric Therapy</u> Ampicillin* 2 g IV q6h + Gentamicin* 5 mg/kg IV q24h</p> <p><u>Anaphylactic PCN/Cephalosporin Allergy</u> Clindamycin 900 mg IV q8h + Gentamicin* 5 mg/kg IV q24h</p>	<p>Continue until patient is clinically improved and afebrile for 24-48 hours</p>	<ul style="list-style-type: none"> Therapeutic drug monitoring may be necessary and dosing adjustments should be made with PharmD. Adjusted body weight is preferred if actual body weight is greater than ideal body weight. Duration of antibiotic therapy should be extended in the setting of bacteremia (7-14 days total duration). Please follow preoperative surgical antimicrobial prophylaxis for those undergoing cesarean delivery Following cesarean delivery, please refer to “post-partum endometritis” empiric therapy recommendations for patients with suspected infection
<p>Chorioamnionitis with severe sepsis OR septic shock</p>	<p><u>Empiric Therapy</u> Piperacillin-tazobactam* 4.5 g IV q6h + Vancomycin** IV (see nomogram, AUC goal 400-600)</p> <p><u>PCN allergy without anaphylaxis, angioedema, or urticaria</u> Cefepime* 2 g IV q8h + Metronidazole 500 mg PO/IV q8h + Vancomycin** IV (see nomogram, AUC goal 400-600)</p> <p><u>Anaphylactic PCN/Cephalosporin allergy</u> Vancomycin** IV (see nomogram, AUC goal 400-600) + Aztreonam* 2 g IV q8h + Metronidazole 500 mg PO/IV q8h</p>	<p>Sepsis w/o bacteremia: 7-14 days, can step-down to oral therapy when stable (see comment)</p> <p>Sepsis with gram-negative bacteremia: 7-14 days from first negative blood culture with IV antibiotics or oral quinolone if susceptible</p>	<ul style="list-style-type: none"> Oral therapy is not recommended in setting of <i>S. aureus</i> or Enterococcal bacteremia Aztreonam does not have gram-positive activity and should be used in combination with vancomycin. If uterine abscess present, duration of therapy may be extended. MRSA is not a common pathogen and thus addition of vancomycin is only recommended in patients with severe sepsis or septic shock. Vancomycin should be discontinued if MRSA is not isolated once patient is stable. Please follow preoperative surgical antimicrobial prophylaxis for those undergoing cesarean delivery Following cesarean delivery, please refer to “post-partum endometritis” empiric therapy recommendations for patients with suspected infection.

Clinical Setting	Empiric Therapy	Duration	Comments
Obstetrical Infections (Post-partum Endometritis) <ul style="list-style-type: none"> • Anaerobes • <i>Gardnerella vaginalis</i> • Group B streptococcus • <i>Clostridium spp.</i> • Enterobacteriaceae • <i>Chlamydia trachomatis</i> 	<u>Empiric Therapy</u> Cefazolin* 2 g IV q8h + Metronidazole 500 mg PO/IV q8h <u>Anaphylactic PCN/Cephalosporin Allergy</u> Clindamycin 900 mg IV q8h + Gentamicin* 5 mg/kg IV q24h <u>Severe Sepsis OR Septic Shock OR Persistent fevers for 48 hours after starting above therapy</u> Piperacillin-tazobactam* 4.5 g IV q6h + Vancomycin** IV (see nomogram , AUC goal 400-600)	Continue until patient has clinically improved and afebrile for 24 hours.	<ul style="list-style-type: none"> • Extended interval gentamicin dosing (5 mg/kg IV q24h) is preferred. Therapeutic drug monitoring may be necessary and dosing adjustments should be made with PharmD. • Duration of antibiotic therapy should be extended in the setting of bacteremia (7-14 days total duration). • MRSA is not a common pathogen and thus addition of vancomycin is only recommended in patients with severe sepsis, septic shock, or those with persistent fevers. Vancomycin should be discontinued if MRSA is not isolated once patient is stable.

*Dose may need to be [adjusted for renal dysfunction](#)

** For ADULTS: Dose per [vancomycin nomogram](#)

Antimicrobial Subcommittee Approval: 04/17, 06/21	Originated: Unknown
P&T Approval: 05/17, 07/21	Last Revised: 07/2021
Revision History: 03/21: Updated vancomycin dosing & hyperlinks 07/21: Updated PID outpatient recommendation.	

The recommendations in this guide are meant to serve as treatment guidelines for use at Michigan Medicine facilities. If you are an individual experiencing a medical emergency, call 911 immediately. These guidelines should not replace a provider's professional medical advice based on clinical judgment, or be used in lieu of an Infectious Diseases consultation when necessary. As a result of ongoing research, practice guidelines may from time to time change. The authors of these guidelines have made all attempts to ensure the accuracy based on current information, however, due to ongoing research, users of these guidelines are strongly encouraged to confirm the information contained within them through an independent source.

If obtained from a source other than med.umich.edu/asp, please visit the webpage for the most up-to-date document.